Introduction
============

Fibromyalgia is a chronic musculoskeletal pain disorder of unknown aetiology, characterised by widespread pain and muscle tenderness and often accompanied by fatigue, sleep disturbance and depressed mood \[[@B1],[@B2]\]. With an estimated lifetime prevalence of approximately 2% in community samples \[[@B3]\], it accounts for 15% of outpatient rheumatology visits and 5% of primary care visits \[[@B4]\]. The prognosis for symptomatic recovery is generally poor \[[@B5]\]. A wide variety of interventions are used in the management of this disorder, although there is no clear consensus on the treatment of choice and fibromyalgia remains relatively refractory to treatment.

A number of meta-analyses and reviews have been conducted on the pharmacological \[[@B6]-[@B8]\] and non-pharmacological \[[@B9],[@B10]\] treatments available for fibromyalgia. The studies main objectives are to guide clinicians in their everyday practice using evidence-based decisions. However, the aim of our current study is rather different. The high prevalence and clinical impact of fibromyalgia makes it a significant public health problem given its high cost. In Spain and other public health systems, a difficult cost-benefit decision must be taken as to which level of the health care system these patients should be treated in: either in specialised settings, which many patients prefer, or in primary care, which is usually more cost-effective. To our knowledge, there is no published meta-analysis on this subject.

We carried out a systematic review and meta-analysis of all randomised controlled trials (RCTs) of pharmacological and non-pharmacological treatments that are available in standard primary care settings and those that are administered in standard secondary care settings of public health care systems in developed countries for the treatment of fibromyalgia. The aim of this paper is to compare the efficacy of the treatments for fibromyalgia available in both settings using the most important outcomes assessed in this disorder, such as pain, quality of life, depression, etc.

Materials and methods
=====================

We followed the QUOROM guidelines for reporting meta-analyses \[[@B11]\].

Database search
---------------

Published reports of RCTs researching pharmacological or non-pharmacological treatments in patients with fibromyalgia were found in the following databases: MEDLINE (1966--2006), EMBASE (1988--2006), The Cochrane Central Register of Controlled Trials (the Cochrane Library Issue 2006) and Psychinfo (1987--2006). Search strategy is summarised in the additional data file. The search was performed without language restrictions but was limited to RCTs in humans. The last electronic search was undertaken in June 2006. All primary and review articles, as well as their references, were reviewed independently in duplicate. The authors of the original reports were contacted for additional information where needed.

Selection criteria
------------------

Studies were screened for inclusion, by reviewing the title and published abstract, based on the following criteria:

### Type of participants

The studies evaluated the treatment or management of fibromyalgia as indicated by the use of recognised diagnostic criteria, such as American College of Rheumatology (ACR) \[[@B1]\]. Despite the concept of primary fibromyalgia (patients in which fibromyalgia can not be explained by other medical disorders) not being accepted by the ACR, most studies on fibromyalgia, and many of the papers included in the meta-analysis, do accept this distinction. Therefore, it has been maintained to increase comparability.

### Types of studies

The papers described a randomisation of treatment, placebo control and at least one group receiving an active (pharmacological or non-pharmacological) treatment.

### Types of interventions

Treatment can be defined as pharmacological or non-pharmacological, and can be allocated to primary or specialised care. The duration of treatment was at least eight weeks.

### Types of outcomes

Outcomes had to be measurable. One of the major problems in fibromyalgia is the wide variety of outcomes. Seven types of outcomes were included: pain, fatigue, quality of life, global function, anxiety/depression, insomnia and tender points. Each of them were assessed with several questionnaires.

Each study was reviewed in duplicate (by EF and JGC) for inclusion with substantial inter-rater agreement (kappa = 0.7). Disagreements were resolved by a consensus agreement. Reviews and abstracts were not considered. The study selection process flowchart is summarised in Figure [1](#F1){ref-type="fig"}.

![Flowchart showing the process of study selection.](ar2455-1){#F1}

Allocation
----------

All studies included were allocated to a level of health care (primary care or specialised care) and category of treatment (pharmacological or non-pharmacological) by a consensus with substantial inter-rater agreement (kappa = 0.91) from a panel of two general practitioners (RM and JM), a psychiatrist (JGC) and a psychologist (EF). A treatment was considered to be available at the primary care level when most general practitioners from most Western national health services were able to provide that treatment without any specific training. Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} summarise which treatments were allocated to the primary and specialised care groups and to the pharmacological and non-pharmacological treatment groups. We have not included RCTs on acupuncture because of the recent meta-analyses showing that this treatment is not effective \[[@B10]\].

###### 

Allocation of treatments according to level of care

  **Primary care**   **Secondary care**
  ------------------ -------------------------------
  Amitriptyline      Pirlindole
  Tramadol           Tropisetron
  Milnacipran        Dehydroepiandrosterone (DHEA)
  Moclobemide        Pramipexole
  Fluoxetine         Malic acid
  Cyclobenzaprine    Rehabilitation
  Nortriptyline      Laser treatment
  Duloxetine         Hyperbaric oxygen therapy
  Pregabaline        Bright light treatment
  Zolpidem           Aerobic exercise
                     Exercise
                     Stress-reduction treatment
                     Chiropractic management
                     Cognitive behavioural therapy
                     Cognitive educational therapy
                     Education training
                     Behavioural insomnia therapy
                     Music vibration

###### 

Pharmacological and non-pharmacological treatments

  **Pharmacological treatments**   **Non-pharmacological treatments**
  -------------------------------- ------------------------------------
  Amitriptyline                    Hyperbaric oxygen therapy
  Cyclobenzaprine                  Bright light treatment
  Dehydroepiandrosterone (DHEA)    Aerobic exercise
  Duloxetine                       Education training
  Fluoxetine                       Behavioural therapy
  Malic acid                       Cognitive behavioural therapy
  Milnacipran                      Cognitive educational therapy
  Moclobemide                      Exercise
  Nortriptyline                    Rehabilitation
  Pirlindole                       Music vibration
  Pramipexole                      Chiropractic management
  Pregabaline                      Stress-reduction treatment
  Tramadol                         Behavioural insomnia therapy
  Tropisetron                      Laser
  Zolpidem                         

Validity assessment
-------------------

All included reports were then independently read by two reviewers (EF and JGC) who assessed the validity of the studies using the modified Oxford Scale (Table [3](#T3){ref-type="table"}) \[[@B12],[@B13]\]. The minimum score of an included trial was one and the maximum was six. Discrepancies were resolved by discussion or by consulting a third reviewer (RM).

###### 

Modified Oxford Scale. Validity score (0 to 7)

  ----------------------------- --
  Randomisation                 
   0 None                       
   1 Mentioned                  
   2 Described and adequate     
                                
  Concealment of allocation     
   0 None                       
   1 Yes                        
                                
  Double blinding               
   0 None                       
   1 Mentioned                  
   2 Described and adequate     
                                
  Flow of patients              
   0 None                       
   1 Described but incomplete   
   2 Described and adequate     
  ----------------------------- --

Data abstraction
----------------

A data abstraction form was created and the following data were included: number of patients and controls, gender (percentage of women), age (median), diagnosis, time of evolution of the disorder (years), severity of the disorder, level of health care (primary care or specialised), kind of treatment (pharmacological or non pharmacological), duration of treatment, modified Oxford Scale ratings and outcomes (ratings in different used scales of quality of life, pain, depression, anxiety, etc).

Meta-analyses
-------------

Both dichotomous and continuous data were extracted. Continuous data were analysed as standardised differences in the means (SDM) with 95% confidence intervals (CI). Where mean values and standard deviations were not reported, the authors of the studies were contacted. If they did not reply and the data were presented graphically, data were extracted from the graphs. If this was not possible, the data were not considered. A random effects model was used by default. Analyses were performed using Comprehensive Meta-analysis, version 2 (Biostat, Englewood, NJ, USA). Data were graphically plotted using forest plots to evaluate treatment effects. Clinical heterogeneity was minimised using stringent diagnostic criteria for fibromyalgia and homogeneous criteria for the treatments and outcomes of the studies included in the meta-analysis.

Results
=======

Literature search and study selection
-------------------------------------

We first performed our literature search in MEDLINE (374 hits), followed by EMBASE (133 hits), and subsequently in the Cochrane Library (41 hits) and in Psychinfo (34 hits). By checking references, we identified an additional 12 hits, resulting in a total of 594 articles (Figure [1](#F1){ref-type="fig"}). Based on titles and abstracts, 102 full articles were retrieved, 33 of which met the inclusion criteria \[[@B14]-[@B46]\]. These 33 studies are summarised in Table [4](#T4){ref-type="table"}.

###### 

Characteristics of the 33 selected randomised controlled trials and the patients studied in them

  N    **Randomized controlled trial**   **Year**   **Country**   **Treatment**                                      **Level of care**                                          **% of women**   **Mean age**   **Length of treatment (years)**   **Simple size**   **Oxford scoring (quality)**   **Duration of disease at baseline (years)**   **Instruments used (outcome assessed)**
  ---- --------------------------------- ---------- ------------- -------------------------------------------------- ---------------------------------------------------------- ---------------- -------------- --------------------------------- ----------------- ------------------------------ --------------------------------------------- -------------------------------------------------------------
  1    Carette                           94         Canada        Amitryptiline Cyclobenzaprine                      Primary care                                               93.8             44.4           24                                208               3                              7.7                                           Mc Gill-BPI (p) SIP (gf)
  2    Russell                           94         USA           Malic acid                                         Specialised care                                           90               49.5           8                                 24                3                                                                            VAS (p) TPI (tp)
  3    Wolfe                             94         USA           Fluoxetine                                         Primary care                                               100              50.4           3                                 42                5                              13                                            TPI (tp) BDI (ad)
  4    Carette                           95         Canada        Amitryptiline                                      Primary care                                               95.5             43.8           8                                 22                2                              6.9                                           VAS (p) VAS (i) VAS (gf)
  5    Chesky                            95         USA           Music vibration                                    Specialised care                                           92.6             48.8           30 minutes                        26                3                              11                                            VAS (p) TPI (tp)
  6    Goldenberg                        96         USA           Fluoxetine Amitryptiline                           Primary care                                               90.3             43             6                                 31                5                              5.7                                           VAS (p) FIQ (GF) BDI (ad) VAS (i) VAS (gf) VAS (f) TPI (tp)
  7    Ginsberg                          96         Belgium       Amitryptiline                                      Primary care                                               82.5             46             8                                 46                2                              32                                            VAS (p) VAS (i) TPI (tp) VAS (f) VAS (gf) NTP (tp)
  8    Moldofsky                         96         Canada        Zolpidem                                           Primary care                                               95               42             2.5                               19                4                                                                            NTP (tp) PGI (i)
  9    Vlayen                            96         Holland       Cognitive behavioural therapy Education training   Specialised care                                           87               44             6                                 131               5                              10                                            BDI (ad)
  10   Wigers                            96         Norway        Aerobic exercise Stress-reduction treatment        Specialised care                                           92               44             14                                48                3                              10                                            VAS (p) VAS (i) VAS (f)
  11   Pearl                             96         Canada        Bright light treatment                             Specialised care                                           100              38             10                                14                2                              5                                             VAS (p) VAS (f) VAS (i)
  12   Kelli                             97         Canada        Chiropractic treatment                             Specialised care                                           \-               49             4                                 19                4                              8                                             VAS (p) NTP (tp)
  13   Hannonen                          98         Finland       Moclobemide Amitryptiline                          Primary care                                               100              49             12                                130               5                              11.2                                          NTP (tp) VAS (p) VAS (f) VAS (i)
  14   Yavuzer                           98         Turkey        Moclobemide                                        Primary care                                               58               33             6                                 60                1                                                                            TPI (tp)
  15   Ginsberg                          98         Belgium       Pirlindole                                         Specialised care                                           85               40             4                                 61                4                              2.9                                           VAS (p) TPI (tp) VAS (gf)
  16   Russell                           00         USA           Tramadol                                           Primary care                                               94               49             6                                 69                4                              4.7                                           VAS (p) FIQ (gf) NTP (tp)
  17   Heymann                           01         Brazil        Amitryptiline Nortryptiline                        Primary care                                               100              50             8                                 118               4                                                                            FIQ (gf) NTP (tp)
  18   Färber                            01         Germany       Tropisetron                                        Specialised care                                           92               48             1.5                               403               3                              11                                            Vas (p) NTP (tp)
  19   Gowans                            01         Canada        Exercise                                           Specialised care                                           88               47             23                                50                3                              9                                             FIQ (gf) BDI (ad) STAI (ad) NTP (tp)
  20   Mannerkorpi                       01         Sweden        Education training                                 Specialised care                                           100              46             24                                58                4                              8.7                                           FIQ (gf) QOLS (ql)
  21   Gür                               02         Turkey        Laser Amitryptiline                                Primary care (Amytriptiline) -- Specialised care (laser)   80               30             8                                 75                3                              4.6                                           HADS (ad) FIQ (gf)
  22   Joaquim                           02         Sweden        Education training Behavioural therapy             Specialised care                                           100              45             12                                53                6                              3.6 pain                                      FIQ (gf) Mc Gill (p)
  23   King                              02         Canada        Exercise Education training                        Specialised care                                           100              46             12                                152               4                                                                            FIQ (gf) NTP (tp)
  24   Lemstra                           05         Canada        Rehabilitation                                     Specialised care                                           84.5             49.5           6                                 79                3                              10                                            VAS (p) BDI (ad)
  25   Schachter                         03         Canada        Aerobic exercise (long-term and short-term)        Specialised care                                           100              42             16                                143               4                              3.5                                           VAS (p) FIQ (gf)
  26   Arnold                            04         USA           Duloxetine                                         Primary care                                               88               49             12                                207               6                              8.9                                           BDI (ad) BPI (ad) NTP (tp) CGI (gf) FIQ (gf)
  27   Yildiz                            04         Turkey        Hyperbaric oxigen therapy                          Specialised care                                           70               40             2.5                               50                2                              4.5                                           VAS (p) NTP (tp)
  28   Crofford                          05         USA           Pregabaline                                        Primary care                                               92               48.5           8                                 529               5                              9                                             VAS (p) MAF (f)
  29   Arnold                            05         USA           Duloxetine                                         Primary care                                               100              50             12                                354               5                                                                            BPI (ad)
  30   Gendreau                          05         USA           Milnacipran                                        Primary care                                               98               47             12                                125               6                              4.1                                           FIQ (gf)
  31   Finckh                            05         Switzerland   Dehydroepiandrosterone (DHA)                       Specialised care                                           100              59             12                                52                6                              13                                            HADS (ad) VAS (f)
  32   Holman                            05         USA           Pramipexole                                        Specialised care                                           94.4             48.5           14                                60                6                              8.4                                           BDI (ad) HAMD (ad) TPI (tp) FIQ (gf)
  33   Edinger                           05         USA           Cognitive behavioural therapy Sleep hygiene        Specialised care                                           100              49             6                                 47                3                                                                            Mc Gill (p) BPI (ad) SF-36 (ql)

Outcome types: P, Pain; QL, Quality of life; AD, Anxiety-depression; I, Insomnia; TP, Tender points; F, Fatigue; GF, Global Function.

Questionnaires: Mc Gill PQ, Mc Gill Pain Questionnaire; BPI, Brief Pain Inventory; VAS, Visual Analogue Scale; QOLS, Quality of Life Scale; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale; HDS, Hamilton Depression Scale; STAI, State-trait Anxiety Inventory; PGI, Patient Global Impression; TPI, Tender Points Index; MAF, Multi-dimensional Assessment of Fatigue; FIQ, Fibromyalgia Impact Questionnaire; CGIS, Clinical Global Impression of Severity; SIP, Sickness Impact Profile.

Of the 69 studies that were excluded 23 were not an RCT; the patient population of 28 were not primary fibromyalgia (but secondary fibromyalgia or allied conditions) or the fibromyalgia criteria used were not ACR criteria \[[@B1]\]; in 16 studies the intervention had a duration shorter than eight weeks or it was so specific that it was not available in standard Western health care systems \[[@B47]\]; and two studies did not use comparable outcome measures. There was seven types of outcomes used in the studies selected from 16 questionnaires or tests summarised in Table [5](#T5){ref-type="table"}.

###### 

Questionnaires and outcome types used in the studies selected

  [Type of outcome]{.ul}        [Questionnaires]{.ul}
  ----------------------------- ------------------------------------------------------------------------------------------
  Pain (p)                      McGill Pain Questionnaire \[[@B48]\]
                                Brief Pain Inventory \[[@B49]\]
                                Visual Analogue Scale \[[@B50]\]
  Quality of life (ql)          SF-36 \[[@B51]\]
                                Quality of Life Scale (QOLS) \[[@B52]\]
  Anxiety and depression (ad)   Beck Depression Inventory \[[@B53]\]
                                Hospital Anxiety and Depression Scale \[[@B54]\]
                                Hamilton Depression Scale \[[@B55]\]
                                State-trait Anxiety Inventory \[[@B56]\]
  Insomnia (i)                  Visual Analog Scale \[[@B50]\]
                                Patient Global Impression \[[@B57]\]
  Tender points (tp)            Tender Points Index \[[@B58]\]
                                Number of Tender Points according to American College of Rheumatology criteria \[[@B1]\]
  Fatigue (f)                   Visual Analog Scale \[[@B50]\]
                                Multi-dimensional Assessment of Fatigue \[[@B59]\]
  Global Function (gf)          Visual Analog Scale \[[@B50]\]
                                Fibromyalgia Impact Questionnaire \[[@B60]\]
                                Clinical Global Impression of Severity \[[@B57]\]
                                Sickness Impact Profile (SIP) \[[@B61]\]

Methodological quality of the included studies
----------------------------------------------

Only 11 of the 33 included studies (33.3%) showed a rating of 5+ on the modified Oxford Scale, that is, a score of high methodological quality. Most of them (nine of 11) were pharmacological studies and the remaining two studies were psychological interventions. Many of them were recent studies, carried out in 2004 and 2005 (six of 11), as can be seen in Tables [4](#T4){ref-type="table"} and [6](#T6){ref-type="table"}. The most commonly absent items were an adequate description of the flow of patients and adequate description of double blinding.

###### 

Characteristics of the patients included in the meta-analysis

                                         **Total**   \%      **Control group**   \%      **Intervention group**   \%
  -------------------------------------- ----------- ------- ------------------- ------- ------------------------ -------
  **Level of care**                                                                                               
  Primary care                           4505        57.8    2127                57.6    2378                     58.1
  Specialised care                       3284        42.2    1567                42.4    1717                     41.9
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Kind of treatment**                                                                                           
  Pharmacological                        5706        73.3    2684                72.7    3022                     73.8
  Non-pharmacological                    2083        26.7    1010                27.3    1073                     26.2
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Outcome assessed**                                                                                            
  Anxiety/depression                     1195        15.3    570                 15.4    625                      15.3
  Quality of life                        115         1.5     51                  1.4     64                       1.6
  Pain                                   2074        26.6    980                 26.5    1094                     26.7
  Fatigue                                650         8.3     320                 8.7     330                      8.1
  Tender points                          1533        19.7    738                 20.0    795                      19.4
  Insomnia                               397         5.1     196                 5.3     201                      4.9
  Global function                        1825        23.4    839                 22.7    986                      24.1
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Methodological quality**                                                                                      
  1 to 2                                 595         7.6     289                 7.8     306                      7.5
  3 to 4                                 3396        43.6    1577                42.7    1819                     44.4
  5 to 6                                 3798        48.8    1828                49.5    1970                     48.1
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Length of treatment (weeks)**                                                                                 
  0 to 8                                 3644        46.8    1750                47.4    1894                     46.3
  09 to 16                               3467        44.5    1678                45.4    1789                     43.7
  17 to 24                               678         8.7     266                 7.2     412                      10.1
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Age**                                                                                                         
  30 to 39                               253         3.2     125                 3.4     128                      3.1
  40 to 49                               6662        85.5    3140                85.0    3522                     86.0
  50 to 59                               874         11.2    429                 11.6    445                      10.9
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Percentage of women**                                                                                         
  \< 80                                  151         1.9     73                  2.0     78                       1.9
  80 to 89                               2258        29.0    1111                30.1    1147                     28.0
  90 to 99                               2874        36.9    1297                35.1    1577                     38.5
  100                                    2506        32.2    1213                32.8    1293                     31.6
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Duration of the disorder (years)**                                                                            
  0 to 5                                 1459        25.3    710                 26.3    749                      24.5
  6 to 10                                2987        51.9    1344                49.7    1643                     53.8
  11 to 15                               1310        22.8    649                 24.0    661                      21.7
  Overall                                5756        100.0   2703                100.0   3053                     100.0
                                                                                                                  
  **Country**                                                                                                     
  Germany                                410         5.3     206                 5.6     204                      5.0
  Belgium                                459         5.9     216                 5.8     243                      5.9
  Brasil                                 278         3.6     132                 3.6     146                      3.6
  Canada                                 1655        21.2    737                 20.0    918                      22.4
  Finland                                488         6.3     240                 6.5     248                      6.1
  Holland                                174         2.2     86                  2.3     88                       2.1
  Norway                                 195         2.5     102                 2.8     93                       2.3
  Sweden                                 254         3.3     126                 3.4     128                      3.1
  Switzerland                            276         3.5     135                 3.7     141                      3.4
  Turkey                                 298         3.8     148                 4.0     150                      3.7
  USA                                    3302        42.4    1566                42.4    1736                     42.4
  Overall                                7789        100.0   3694                100.0   4095                     100.0
                                                                                                                  
  **Year of publication**                                                                                         
  1994                                   620         8.0     234                 6.3     386                      9.4
  1995                                   178         2.3     86                  2.3     92                       2,.2
  1996                                   1306        16.8    637                 17.2    669                      16.3
  1997                                   38          0.5     18                  0.5     20                       0.5
  1998                                   724         9.3     349                 9.4     375                      9.2
  2000                                   207         2.7     102                 2.8     105                      2.6
  2001                                   926         11.9    460                 12.5    466                      11.4
  2002                                   780         10.0    372                 10.1    408                      10.0
  2003                                   392         5.0     196                 5.3     196                      4.8
  2004                                   1241        15.9    621                 16.8    620                      15.1
  2005                                   1377        17.7    619                 16.8    758                      18.5
  Overall                                7789        100.0   3694                100.0   4095                     100.0

Study characteristics
---------------------

The review selected 33 RCTs that assessed 120 treatment interventions on 7789 patients diagnosed with primary fibromyalgia according to ACR criteria \[[@B1]\]. Of these, 4505 (57.8%) were included in the primary care group and 3284 (42.2%) in the specialised intervention group. The characteristics of the patients included in these studies are summarised in Table [6](#T6){ref-type="table"}. The sample was made up of middle-aged women, who had the disorder for between six and 10 years (51.9%), treated mainly with pharmacological approaches (73.3%). The outcome types most frequently assessed were pain (26.6%) and global function (23.4%). Most of the patients were from studies carried out in the USA and Canada (63.6%) and were published after 2000 (61.5%). There were no significant differences in any of the variables studied between control and intervention groups.

The mean effect size of the efficacy of the 120 treatment interventions on patients with fibromyalgia compared with efficacy in controls, regardless of the outcome type assessed or the questionnaire used, was 0.49 (95%CI = 0.39 to 0.58; p \< 0.001). This is a medium size effect \[[@B62]\], but it is significant. When we compared the efficacy of these treatments on fibromyalgia, after allocating the treatments to primary or specialised level of care, regardless of the type of outcome assessed or the questionnaire used, mean effect size of efficacy in primary care was 0.46 (95%CI = 0.33 to 0.58) while in specialised care was 0.53 (95%CI = 0.38 to 0.69. These differences are not significant.

When we analysed the efficacy of treatments on the different fibromyalgia outcome types (Table [7](#T7){ref-type="table"}), we observed that there is an overlapping of the interval scores comparing primary and specialised care for all outcome types. This means that there are no significant differences. There are insignificant differences favouring secondary or specialised care for tender points (mean = 0.28; 95% CI = 0.12 to 0.68 for primary care; mean = 0.50, 95% CI = 0.0 to 1.0 for specialised care) and pain (mean = 0.48, 95% CI = 0.30 to 0.66 for primary care; mean = 0.73, 95% CI = 0.41 to 1.05 for specialised care). On the other hand, there are insignificant differences in favour of primary care for insomnia (mean = 0.57, 95% CI = 0.15 to 0.99 for primary care; mean = -0.18, 95% CI = -0.62 to 0.27 for specialised care), anxiety/depression (mean = 0.59, 95% CI = 0.10 to 1.08 for primary care; mean = 0.40, 95% CI = 0.12 to 0.67 for specialised care), and fatigue (mean = 0.30, 95% CI = 0.05 to 0.56 for primary care; mean = 0.22, 95% CI = -0.08 to 0.52 for specialised care). For specialized care, there are minimal differences also nonsignificant (surely the cause is higher heterogeneity in these studies). Global function, thought to capture the whole impact of the disease, was quite similar in both levels of care (0.53 in primary care; 0.54 in specialised care). The quality of life outcome could not be compared because there were no studies in primary care assessing this variable.

###### 

Efficacy of treatments by fibromyalgia outcomes according to level of care

  **Global function**   **Pain**           **Tender points**   **Quality of life**   **Anxiety/depression**   **Insomnia**       **Fatigue**                                                                                                                                                               
  --------------------- ------------------ ------------------- --------------------- ------------------------ ------------------ -------------- ------------------ -------------- ------------------ -------------- ------------------ -------------- ------ ----------- ------- ------ ---------- ------- ------
  Low-Up Limit          Std dif in means   Low-Up Limit        Std dif in means      Low-Up Limit             Std dif in means   Low-Up Limit   Std dif in means   Low-Up Limit   Std dif in means   Low-Up Limit   Std dif in means   Low-Up Limit                                                        
                                                                                                                                                                                                                                                                                                           
  0.30                  0.76               **0.48**            0.30                  0.66                     **0.28**           -0.12          0.68                                                                **0.59**           0.10           1.08   **0.57**    0.15    0.99   **0.30**   0.05    0.56
  0.32                  0.77               **0.73**            0.41                  1.05                     **0.50**           0.00           1.00               **1.22**       0.49               1.95           **0.40**           0.12           0.67   **-0.18**   -0.62   0.27   **0.22**   -0.08   0.52
  0.38                  0.69               **0.54**            0.38                  0.70                     **0.37**           0.05           0.68               **1.22**       0.49               1.95           **0.44**           0.20           \#\#   **0.22**    -0.09   0.52   **0.27**   0.07    0.46

As an example, we have included the efficacy of the treatments allocated to both levels of care in the outcome of pain in patients with fibromyalgia (Figure [2](#F2){ref-type="fig"}). This outcome is one of the most important in this disorder and the most thoroughly assessed in the studies reviewed. We can observe that there are insignificant differences favouring specialised care (0.73 for specialised care; 0.48 for primary care). However, in this figure, we can also see that heterogeneity in specialised care treatment is higher than in primary care treatment. In fact, there are two studies \[[@B40],[@B46]\] with outcomes of 3.18 and 2.49, respectively, which are the source of this difference. This higher heterogeneity in specialised care treatments compared with primary care treatments is also found in the remaining types of outcome.

![Efficacy of the treatments allocated to both levels of care according to the type of pain in patients with fibromyalgia.](ar2455-2){#F2}

In Table [8](#T8){ref-type="table"} we can see the influence of moderating variables on all of the outcomes assessed (overall efficacy), on the specific outcome Global function and on the Fibromyalgia Impact Questionnaire (FIQ). Obviously, we could have included other outcomes and questionnaires but owing to the great amount of information, we selected these variables because they seem to be the most used in assessing the efficacy of fibromyalgia treatments. The results when the other outcomes or questionnaires are analysed are quite similar.

###### 

Influence of moderating variables on all the outcomes assessed, on the Fibromyalgia Impact Questionnaire and on the Global Function

                                     **All the outcome assessed**   **Fibromyalgia Impact Questionnaire**   **Global function**                                                                                             
  ---------------------------------- ------------------------------ --------------------------------------- --------------------- --------- ------------------ ------- ------- --------- ------------------ ------- ------- ---------
                                     Std dif in means               Lower                                   Upper                 p-value   Std dif in means   Lower   Upper   p-value   Std dif in means   Lower   Upper   p-value
                                                                                                                                                                                                                            
  **Methodological quality**                                                                                                                                                                                                
  1 to 2                             **1,21**                       0.74                                    1.69                  0.000                                                  **1.40**           0.75    2.04    0.000
  3 to 4                             **0.57**                       0.42                                    0.72                  0.000     **0.66**           0.37    0.95    0.000     **0.58**           0.33    0.83    0.000
  5 to 6                             **0.23**                       0.14                                    0.31                  0.000     **0.36**           0.18    0.55    0.000     **0.37**           0.22    0.51    0.000
  **Overall**                        **0.33**                       0.26                                    0.41                  0.000     **0.45**           0.29    0.60    0.000     **0.46**           0.33    0.58    0.000
                                                                                                                                                                                                                            
  **Kind of treatment**                                                                                                                                                                                                     
  Pharmacological                    **0.42**                       0.32                                    0.53                  0.000     **0.59**           0.29    0.89    0.000     **0.54**           0.33    0.74    0.000
  Non-pharmacological                **0.63**                       0.43                                    0.83                  0.000     **0.52**           0.26    0.79    0.000     **0.52**           0.26    0.79    0.000
  **Overall**                        **0.47**                       0.37                                    0.56                  0.000     **0.55**           0.35    0.75    0.000     **0.53**           0.37    0.70    0.000
                                                                                                                                                                                                                            
  **Length of treatment (weeks)**                                                                                                                                                                                           
  0 to 8                             **0.73**                       0.57                                    0.89                  0.000     **0.83**           0.35    1.30    0.001     **0.82**           0.50    1.14    0.000
  9 to16                             **0.20**                       0.11                                    0.28                  0.000     **0.35**           0.20    0.49    0.000     **0.33**           0.20    0.46    0.000
  17 to 24                           **0.36**                       0.14                                    0.58                  0.001     **0.73**           0.29    1.16    0.001     **0.35**           -0.01   0.71    0.055
  **Overall**                        **0.31**                       0.24                                    0.38                  0.000     **0.42**           0.29    0.55    0.000     **0.40**           0.28    0.51    0.000
                                                                                                                                                                                                                            
  **Age**                                                                                                                                                                                                                   
  30 to 39                           **1.41**                       0.95                                    1.88                  0.000     **1.41**           0.97    1.85    0.000     **1.41**           0.97    1.85    0.000
  40 to 49                           **0.44**                       0.35                                    0.54                  0.000     **0.37**           0.25    0.50    0.000     **0.39**           0.28    0.51    0.000
  50 to 59                           **0.50**                       0.12                                    0.88                  0.010     **0.99**           -0.22   2.20    0.108     **0.99**           -0.22   2.20    0.108
  **Overall**                        **0.48**                       0.39                                    0.58                  0.000     **0.46**           0.34    0.58    0.000     **0.47**           0.35    0.58    0.000
                                                                                                                                                                                                                            
  **Women (%)**                                                                                                                                                                                                             
  **\< 80**                          **3.22**                       0.68                                    5.76                  0.013                                                                                     
  80 to 89                           **0.70**                       0.49                                    0.91                  0.000     **0.96**           0.30    1.62    0.004     **0.85**           0.46    1.24    0.000
  90 to 99                           **0.33**                       0.23                                    0.44                  0.000     **0.37**           0.13    0.61    0.002     **0.31**           0.14    0.47    0.000
  100                                **0.40**                       0.25                                    0.55                  0.000     **0.50**           0.23    0.78    0.000     **0.50**           0.23    0.78    0.000
  **Overall**                        **0.41**                       0.33                                    0.49                  0.000     **0.46**           0.29    0.64    0.000     **0.42**           0.28    0.55    0.000
                                                                                                                                                                                                                            
  **Duration of disorder (years)**                                                                                                                                                                                          
  0 to 5                             **0.85**                       0.57                                    1.13                  0.000     **0.57**           0.21    0.93    0.002     **0.66**           0.34    0.98    0.000
  6 to10                             **0.36**                       0.27                                    0.45                  0.000     **0.45**           0.26    0.64    0.000     **0.38**           0.22    0.54    0.000
  11 to15                            **0.16**                       0.02                                    0.29                  0.023                                                                                     
  **Overall**                        **0.36**                       0.29                                    0.43                  0.000     **0.49**           0.33    0.65    0.000     **0.45**           0.31    0.58    0.000
                                                                                                                                                                                                                            
  **Country**                                                                                                                                                                                                               
  Germany                            **0.36**                       0.17                                    0.56                  0.000                                                                                     
  Belgium                            **0.94**                       0.73                                    1.15                  0.000                                                  **1.02**           0.35    1.70    0.003
  Brazil                             **1.13**                       0.46                                    1.80                  0.001     **0.99**           -0.22   2.20    0.108     **0.99**           -0.22   2.20    0.108
  Canada                             **0.35**                       0.20                                    0.50                  0.000     **0.38**           0.17    0.59    0.000     **0.29**           0.11    0.46    0.001
  Finland                            **0.10**                       -0.08                                   0.28                  0.283                                                                                     
  Netherlands                        **0.09**                       -0.21                                   0.39                  0.567                                                                                     
  Norway                             **0.30**                       -0.11                                   0.71                  0.157                                                                                     
  Sweden                             **0.35**                       0.05                                    0.64                  0.022     **0.45**           0.03    0.88    0.038     **0.45**           0.03    0.88    0.038
  Switzerland                        **0.02**                       -0.21                                   0.26                  0.836                                                                                     
  Turkey                             **2.19**                       1.31                                    3.08                  0.000     **1.41**           0.97    1.85    0.000     **1.41**           0.97    1.85    0.000
  USA                                **0.39**                       0.26                                    0.51                  0.000     **0.34**           0.16    0.53    0.000     **0.36**           0.21    0.50    0.000
  **Overall**                        **0.36**                       0.30                                    0.43                  0.000     **0.46**           0.33    0.58    0.000     **0.42**           0.31    0.52    0.000

In Table [8](#T8){ref-type="table"} we can also see that an improvement in the methodological quality of the studies is accompanied by a reduction in size effect in the Global Function outcome (the same is found for FIQ scores or for overall efficacy), owing to lesser heterogeneity. Type of treatment, whether pharmacological or non-pharmacological, did not modify the mean effect size in any of the three variables assessed.

On the contrary, shorter length of treatment favours differences that increase size effect. However, these differences can be explained by higher heterogeneity in the studies with shorter treatments, as can be seen on Figure [2](#F2){ref-type="fig"} and not by a decrease in the therapeutic effect in longer treatments. With regard to mean participant age, we can observe higher improvement in all outcomes assessed in younger patients. However, the number of studies that evaluate the period of age extremes (young and older people) and assess overall efficacy is low. There are no differences in outcome in relation to gender in any of the three variables evaluated. Finally, the duration of the disorder influences the outcome: a shorter evolution of the disease is associated with higher improvement in any outcome. Again, the number of these kinds of studies is low and heterogeneity is greater, so interpretation of the results is more subjective.

Statistical heterogeneity has been assessed by inconsistence \[[@B63]\]; in our study this is 75%, which is considered to be highly inconsistent. In these cases, the use of random effects analysis is recommended, which we did. A funnel plot between standard error and mean standardised difference, a quality measure to assess publication bias, indicates that most studies are distributed around the central line and are placed in the middle of the graph. There are some small sample studies scattered on the right and on the lower part of the graph that imbalance the weight towards positive values.

Discussion
==========

There have been studies assessing multi-modal treatments in primary care \[[@B64]\] and trying to improve the efficacy of primary care treatments for patients with fibromyalgia through better communication \[[@B65]\]. However, to the best of our knowledge this is the first meta-analysis on the efficacy of the treatment of fibromyalgia according to level of care. The clinical and economical relevance of this disorder makes this a key question of research in free, universal health systems in which general practitioners are the gateway to the system. Prevalent and chronic disorders such as fibromyalgia are a huge cost to the health care system \[[@B3]\] and it is necessary to demonstrate whether treatment in a specialised care setting improves the outcome compared with its routine management in a primary care setting.

Only 33 studies from 594 papers examined met the inclusion criteria of our study. These 33 RCTs assessed 120 treatment interventions on patients diagnosed with primary fibromyalgia, 4505 (57.8%) of whom were allocated to primary care and 3284 (42.2%) to specialised care. The sample was made up of middle-aged women, with an average duration of the disorder of six to 10 years, mainly treated with pharmacological approaches. Most of the studies were carried out in the USA and Canada and were published after 2000. Owing to the great variety of outcomes and questionnaires used to assess the patients, we have summarised the results of the most frequently used in the studies revised: global function, pain and FIQ. The quality of the studies was rather low with only one-third of them rating 5+ on the Oxford Scale.

The studies by Yildiz and colleagues \[[@B40]\] and Edinger and colleagues \[[@B46]\] could be considered as \"outliers\" because the treatments assessed in both studies were much more efficacious than the other treatments allocated to specialised care, but the size sample in both studies was small and the duration of treatment somewhat short. However, we have not ruled out these two studies from the meta-analysis for the following reasons:

• These studies fulfil the stringent selection criteria of the meta-analysis. Methodological quality was rated independently and this variable is not an exclusion criteria.

• We expected this meta-analysis to show great heterogeneity owing to the different kinds of treatments included. We can not eliminate these studies merely as a result of their heterogeneity, since they are as valuable as the other studies included. We have used a random effects model for the analysis.

• Both studies assess non-pharmacological treatments and both were allocated to specialised care. To exclude them could bias the study towards pharmacological treatments and primary care.

• We recalculated the meta-analysis excluding these two studies and the results were the same: there were no significant differences in the efficacy of the treatments for fibromyalgia when comparing primary care and specialised care.

Our meta-analysis demonstrates that there are no differences in the overall outcome of fibromyalgia regardless of the level of care in which the patient is treated. This article only summarises some outcomes and questionnaires, but we have not found differences favouring either specialised or primary care for any of the seven outcomes or the many questionnaires assessed. In the case of quality of life, the two levels of care could not be compared. We consider that the external validity of these data is high because the selection criteria of the studies allow it to be generalised to most western health services. However, with respect to internal validity, this data should be analysed cautiously because statistical heterogeneity was important for specialised care studies whereas primary care studies show great homogeneity. In any case, the study points to moderate efficacy of any of the treatments described for fibromyalgia and similar efficacy in both primary and specialised levels of care.

Two of the variables that improve treatment efficacy in fibromyalgia are low quality of the studies and shorter duration of treatment, although both of these are biased by the heterogeneity of the studies. Other variables that also improve outcome, which are not biased by the heterogeneity of the studies, are younger patient age and shorter duration of the disorder. In elderly patients, treatment efficacy shows no significant difference when compared with the control group. However, gender and type of treatment (pharmacological vs. psychological) are not related to outcome. These results insist on the importance of an early diagnosis of the disorder, a fact that is usually related to a younger age of the patient.

Three are three main limitations to this research:

• Heterogeneity of the disorder: there are considered to be several subgroups of patients with fibromyalgia \[[@B66]\], so each of them could have different treatment of choice and, consequently, the results of this study could be different for every subgroup.

• The variability of outcomes used in fibromyalgia: it is difficult to obtain a single outcome summarising the efficacy of the treatment.

• Allocation of treatments to a level of care is a subjective matter: some treatments are new and we cannot foresee which level they will be used at, while others that can theoretically be used in primary care are scarcely utilised at this level. Decisions on which level these should be allocated to had been attained by agreement among four clinicians belonging to different levels and several specialities. Another criticism could be that all the treatments allocated to primary care could also be used at a specialist level, so the comparison should have been primary care treatments vs. all fibromyalgia treatments. However, we did not used this approach because our aim was to assess what was the added value in using specialised treatments for increasing efficacy of fibromyalgia treatment.

The health system operating in Spain is quite similar to the UK and Dutch health systems and is also comparable to other European and Western health systems, with some modifications. The Spanish health system is available to all Spaniards and citizens of the EU and is completely free at all levels. For this reason, there are no economic limitations to accessibility to the system in Spain, and only geographical limitations may exist (inhabitants of small and isolated mountain villages would have more difficulty accessing large hospitals). In this sense, the results of our study could be useful for most Western health systems. Obviously, the results of the meta-analysis are more difficult to extrapolate to countries such as the USA where primary care is not the entrance gate to the system. However, the most important conclusion that can be extrapolated from the study is that family doctors can see similar improvements in their patients with their treatment than specialised clinics in the management of patients with fibromyalgia.

Conclusion
==========

Based on this meta-analysis and despite the heterogeneity of specialised care studies, and of the other limitations described, there is no clear indicator for treating fibromyalgia in specialised care or for the development of specialised units for the treatment of this disorder. According to this study, the same moderate efficacy can be obtained in primary care settings with the routine treatments available at this level. Obviously, any new treatment could upset the balance of this comparison and, whatever the case, new research studies that are more focused on cost-efficacy analysis are necessary to confirm this data.
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